Therapeutic Solutions files Patent on Blood Derived Innate Immune System Stimulator

May 16, 2017 09:00 ET

Company Resurrecting “Transfer Factor” Immunotherapeutic for Treatment of Cancer

OCEANSIDE, CA–(Marketwired – May 16, 2017) – Therapeutics Solutions International, Inc., (OTC PINK: TSOI) announced today the filing of a patent for a novel blood derived stimulator of innate immune cells called “innaMune”.

This is a biological product derived from tissue culture of blood cells derived from healthy donors. It is a combination of cytokines that synergistically maintain activity of innate immune system cells, as well as having ability to shift M2 macrophages to M1, based on in vitro studies performed by the Company. In the 1980’s researchers were developing leukocyte extracts termed “transfer factor”, which generated positive preclinical and some early clinical studies1,2 in cancer. The Company has continued research in this field that was in many ways overlooked by current science, and believes to have identified means of producing the immunologically active ingredients in a scalable and reproducible manner.

“We are fortunate to have a strong scientific network focused on immunology of cancer that understands historical perspectives. In the current Golden Age of Cancer Immunotherapy, it makes a lot of sense to look at an old approach that previously had signals of clinical efficacy, and bring them to the 21st Century,” said Timothy Dixon, President and CEO of Therapeutic Solutions International.

“From a therapeutics development perspective, there is a lot less risk in taking something that already has clinical data, perfecting it, and then entering clinical trials, as compared to starting a project from scratch,” said Dr. Thomas Ichim, Director of Therapeutic Solutions International. “We were pleasantly surprised to see that the innaMune version of transfer factor is potently capable of transferring cancer promoting M2 macrophages to cancer inhibiting M1. We believe that in addition to a monotherapy, innaMune will act as a potent adjuvant to T cell stimulating therapies such as currently used checkpoint inhibitors.”

About Therapeutic Solutions International, Inc.
The Company’s corporate website is www.therapeuticsolutionsint.com. Our new products can be viewed on www.projuvenol.com and products can be ordered at www.youcanordernow.com.

These Supplement products have not been evaluated by the United States Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any diseases.

Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

1 Fujisawa et al. Randomized controlled trial of transfer factor immunochemotherapy as an adjunct to surgical treatment for primary adenocarcinoma of the lung. Jpn J Surg. 1984 Nov;14(6):452-8. https://www.ncbi.nlm.nih.gov/pubmed/6397652

2 Kirsh et al. Transfer factor in the treatment of carcinoma of the lung. Ann Thorac Surg. 1984 Aug;38(2):140-5. https://www.ncbi.nlm.nih.gov/pubmed/6380436

© 2016: Therapeutic Solutions International, Inc., All Rights Reserved | Awesome Theme by: D5 Creation | Powered by: WordPress